Latest Breaking News On - Miguel forte - Page 9 : comparemela.com

Topline results expected in Q3 2021 Gosselies, Belgium, 22 December 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has completed recruitment and treated all patients in its pivotal Phase III clinical study with the improved viscosupplement, JTA-004, in patients with knee osteoarthritis. Topline results are anticipated on the 3-month primary endpoint and 6-month follow-up period in the third quarter of 2021. “ The Covid-19 pandemic has had a substantial impact on the progress of clinical studies globally. As a result, Bone Therapeutics successfully completing patient recruitment of this large clinical study, evaluating more than 700 patients, on time and schedule, is a tremendous achievement. The contribution of patients, clinicians, clinical study operators has been invaluable to achieving this major milestone. The efforts of our partner NBCD

Hong kongFrance generalWaals gewestOlivier godeauxMiguel fortePierre laurentArthur rouillLyvonne briggsJean luc vandebroekNeil hunter michelle boxallLouis victor delouvrierCatherine haquenneNewcap investor relations financial communicationsImage box communicationsInternational media enquiriesEuronext brussels